AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.
The real-world evidence study is evaluating the risk of ACD, hospitalisation for heart failure (hHF), heart attack and stroke in patients with the disease receiving treatment with SGLT-2 inhibitors such as Farxiga (dapagliflozin) versus other glucose-lowering medicines.
The new analysis looked at data from more than 400,000 patients across six countries, 74 percent of whom had no history of established cardiovascular disease.
Results showed that treatment with an SGLT-2i (Farxiga, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin or luseogliflozin) was linked with a 49 percent lower risk of ACD, 36 percent of hHF, 19 percent of MI and 32 percent of stroke compared to other diabetes medicines. There was also a 40 percent lower risk of the composite endpoint of hHF or ACD, AZ said.
“With the majority of patients in this latest analysis being treated with Farxiga, these results suggest there is a strong association of CV benefits with the use of Farxiga across diverse patient ethnic and racial demographics,” noted Elisabeth Björk, vice president, head of Cardiovascular and Metabolic Diseases (CVMD), Global Medicines Development, AZ.
The results were presented at the American College of Cardiology’s 67th Annual Scientific Session and published in the Journal of the American College of Cardiology.
